Lysosomal Therapeutics

 Dana Hilt, M.D., was formerly the Chief Medical Officer for FORUM Pharmaceuticals, where he supported the development of therapies for the treatment of cognitive impairment in schizophrenia and Alzheimer’s disease. He has aided in the development of a variety of potential therapeutics for Parkinson’s, ALS, Alzheimer’s, oncologic diseases, chronic pain, metabolic disorders and inflammatory conditions. He is a former Chief Medical Officer and Senior Vice President of Clinical Research, Medical Affairs and Development for Ascend Therapeutics and is the former Vice President of Clinical Research for Gilford Pharmaceuticals. Dr. Hilt served on the staff of the National Institute of Health for five years. He has co-authored more than 100 publications and book chapters in both basic and clinical neurosciences. Dr. Hilt earned his M.D. from Tufts University School of Medicine and trained in internal medicine at Harvard Medical School and neurology at the Johns Hopkins Hospital.